Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 27, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2023 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has...
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
July 10, 2023 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
May 18, 2023 06:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented...
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
May 09, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease...
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
May 09, 2023 06:55 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023 16:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
May 02, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
March 28, 2023 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...